CN116322769A - 用于治疗多发性骨髓瘤的方法 - Google Patents

用于治疗多发性骨髓瘤的方法 Download PDF

Info

Publication number
CN116322769A
CN116322769A CN202180063247.6A CN202180063247A CN116322769A CN 116322769 A CN116322769 A CN 116322769A CN 202180063247 A CN202180063247 A CN 202180063247A CN 116322769 A CN116322769 A CN 116322769A
Authority
CN
China
Prior art keywords
once
dose
ser
subject
bispecific antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180063247.6A
Other languages
English (en)
Chinese (zh)
Inventor
S·吉尔吉斯
J·戈德堡
B·希尔德
X·马
J·拉塞尔
R·维罗纳
S·杨
K·皮拉里塞蒂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of CN116322769A publication Critical patent/CN116322769A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Luminescent Compositions (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Compression Of Band Width Or Redundancy In Fax (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180063247.6A 2020-09-16 2021-09-16 用于治疗多发性骨髓瘤的方法 Pending CN116322769A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063079294P 2020-09-16 2020-09-16
US63/079294 2020-09-16
US202063116549P 2020-11-20 2020-11-20
US63/116549 2020-11-20
US202163187888P 2021-05-12 2021-05-12
US63/187888 2021-05-12
PCT/EP2021/075523 WO2022058445A1 (en) 2020-09-16 2021-09-16 Methods for treating multiple myeloma

Publications (1)

Publication Number Publication Date
CN116322769A true CN116322769A (zh) 2023-06-23

Family

ID=77924410

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180063247.6A Pending CN116322769A (zh) 2020-09-16 2021-09-16 用于治疗多发性骨髓瘤的方法

Country Status (11)

Country Link
US (1) US20220177584A1 (cg-RX-API-DMAC7.html)
EP (1) EP4213945A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023542124A (cg-RX-API-DMAC7.html)
KR (1) KR20230069959A (cg-RX-API-DMAC7.html)
CN (1) CN116322769A (cg-RX-API-DMAC7.html)
AU (1) AU2021346129A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023004830A2 (cg-RX-API-DMAC7.html)
CA (1) CA3194796A1 (cg-RX-API-DMAC7.html)
IL (1) IL301361A (cg-RX-API-DMAC7.html)
MX (1) MX2023003086A (cg-RX-API-DMAC7.html)
WO (1) WO2022058445A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI781108B (zh) 2016-07-20 2022-10-21 比利時商健生藥品公司 抗gprc5d抗體、結合gprc5d與cd3之雙特異性抗原結合分子及其用途
EP4585615A4 (en) 2022-09-09 2026-07-08 Beijing Mabworks Biotech Co Ltd Multispecific antibody binding to BCMA, GPRC5D and CD3 and its use
CN117924485A (zh) * 2022-10-25 2024-04-26 上海祥耀生物科技有限责任公司 一种抗gprc5d的多特异性抗体
TW202448927A (zh) * 2023-02-28 2024-12-16 美商健生生物科技公司 包含雙特異性gprc5d/cd3抗體之組成物
EP4698217A1 (en) * 2023-04-19 2026-02-25 Janssen Biotech, Inc. Methods for treating multiple myeloma
WO2024246856A1 (en) 2023-06-01 2024-12-05 Janssen Biotech, Inc. Methods for treating multiple myeloma
AU2024370419A1 (en) 2023-10-31 2026-06-11 Janssen Biotech, Inc. Combination regimens for treating multiple myeloma

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
TWI781108B (zh) * 2016-07-20 2022-10-21 比利時商健生藥品公司 抗gprc5d抗體、結合gprc5d與cd3之雙特異性抗原結合分子及其用途
EP3630839A1 (en) * 2017-06-01 2020-04-08 Xencor, Inc. Bispecific antibodies that bind cd 123 cd3
WO2019220368A1 (en) * 2018-05-16 2019-11-21 Janssen Biotech, Inc. Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy
JP2022543553A (ja) * 2019-07-31 2022-10-13 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト Gprc5dに結合する抗体

Also Published As

Publication number Publication date
BR112023004830A2 (pt) 2023-04-18
KR20230069959A (ko) 2023-05-19
IL301361A (en) 2023-05-01
JP2023542124A (ja) 2023-10-05
EP4213945A1 (en) 2023-07-26
CA3194796A1 (en) 2022-03-24
US20220177584A1 (en) 2022-06-09
MX2023003086A (es) 2023-06-16
WO2022058445A1 (en) 2022-03-24
AU2021346129A1 (en) 2023-06-01

Similar Documents

Publication Publication Date Title
CN116249548A (zh) 用于治疗多发性骨髓瘤的方法
US20220177584A1 (en) Methods for treating multiple myeloma
KR20240099376A (ko) 암 치료 및 bcmaxcd3 이중특이성 항체의 효능을 향상시키는 방법
US11591395B2 (en) Methods of treating prostate cancer with an anti-PSMA/CD3 antibody
KR20210118870A (ko) 진행성 단계의 고형 종양 암에 대한 치료용 rna 및 항-pd1 항체
TW201943731A (zh) 用於預防移植物排斥之抗cd40抗體
JP2020519579A (ja) Lrrc33阻害剤およびその使用
US20230131598A1 (en) Combination treatment for cancer
JP2024520898A (ja) 再発性及び/又は難治性多発性骨髄腫の治療をモニタリングするための方法及び組成物
US20250074981A1 (en) Combination therapy with dexamethasone and tumor-specific t cell engaging multi-specific antibodies for treating cancer
KR20250005246A (ko) 항-cd19 작용제에 대한 투여 요법 및 이의 용도
US20230140694A1 (en) Combination treatment for cancer involving anti-icos and anti-pd1 antibodies, optionally further involving anti-tim3 antibodies
US20210079115A1 (en) Methods of treating renal cancer with an anti- psma/cd3 antibody
EP4136105A1 (en) Combination treatment for cancer based upon an icos antibody and a pd-l1 antibody tgf-beta-receptor fusion protein
JP2026514753A (ja) 多発性骨髄腫を治療するための方法
US20250376509A1 (en) Methods for treatment of myeloproliferative neoplasms
JP2026514945A (ja) Aml及び関連障害の治療のためのcd123 nk細胞エンゲージャの使用
KR20260013484A (ko) 암 치료에서 t 세포 인게이징 단백질의 용도
KR20240099371A (ko) 암 치료 및 gprc5dxcd3 이중특이성 항체의 효능을 향상시키는 방법

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination